Kornimate/medical-research-clean huggingface dataset:
visceral adiposity and cvd risk in women

Conditions: Cardiovascular Diseases; Heart Diseases; Obesity; Diabetes Mellitus

Summary: to investigate the influence of total body fat and visceral fat on risk factors of diabetes and cardiovascular disease (cvd) in black and white women.

background: obesity is associated with increased morbidity and mortality. concern about obesity has increased as the prevalence and severity have increased and the age of onset has decreased. it has also become clear that the location of fat may play an important role in determining the risk associated with obesity. intra-abdominal fat has been shown to have particularly adverse consequences related to cardiovascular risk factors. of interest is the fact that a number of studies have shown that the impact of overall adiposity differs by race. for each unit increase in adiposity, blacks appear to have less of an increase in blood pressure and triglycerides and less of a decrease in hdl cholesterol compared to whites. this racial difference in the relationship of adiposity to cardiovascular risk status may be related to differences in the distribution of fat. it is hypothesized that for a given level and increase in total body fat (measured by dexa) black women will have less intra-abdominal fat (measured by magnetic resonance imaging). the cohort to be studied is a defined group of black and white women who were initially recruited into the study as children at age nine or 10 years as part of the national heart, lung and blood institute national growth and health study. the cohort has been maintained and studied continuously over the past 11 to 12 years with about 75 percent of the original cohort remaining. design narrative: subjects will be studied at age 23 and again at age 25 years. at each examination, subjects will have measurement of total fat (dexa), intra-abdominal fat (mri), fasting lipids and lipoproteins, insulin and glucose, blood pressure, and left ventricular mass (by echocardiography). in addition, the timing of pubertal maturation and dietary intake of fat and sucrose will be evaluated as potential determinants of intra-abdominal fat using data previously collected from age nine years to age 22 years. study of this cohort provides a unique opportunity to evaluate whether differences in deposition of intraabdominal fat are related to racial differences in the relationship between adiposity and cardiovascular risk factors. it will also allow evaluation of childhood and adolescent determinants of adult intra-abdominal adiposity. the results of this investigation may provide insight into the prevention of intra-abdominal fat accumulation and ultimate lowering of risk for cardiovascular disease.

Eligibility criteria:
no eligibility criteria
association between telomere length and cardiac dysfunction

Conditions: Cardiac Toxicity; Acute Leukemia; Childhood Cancer

Summary: compelling epidemiological evidence indicates that alterations of relative telomere length (rtl) are associated with cardiac dysfunction caused by chemotherapy in children with acute leukemia (al).the aim of this study was to explore association between rtl content in peripheral blood cells could be used as a risk predictor for severity of cardiac damage.


Eligibility criteria:
inclusion criteria: * 1. histological confirmed acute leukemia; 2. preparing for chemotherapy; exclusion criteria: * 1.history of other malignancy; 2.blood transfusion within one month or prior bone marrow transplantation; 3.patients who reluctant to sign informed consent.
validation study of a new digital diagnostic and treatment test based on interactive video games for alzheimer's disease

Conditions: Alzheimer Disease; MCI

Summary: this study aims to validate a novel, non-invasive diagnostic and digital therapeutic approach for alzheimer's disease (ad), centered on an interactive video game called bgaze therapy. this platform leverages eye-tracking technology to assess and potentially enhance cognitive functions, particularly attention and memory. the diagnostic component of the study investigates the use of eye vergence responses-elicited during a visual attention task-as potential biomarkers for early ad. specifically, the study will re-validate eye vergence by comparing response patterns among three groups: cognitively healthy older adults, individuals with mild cognitive impairment (mci), and patients with confirmed ad, based on blood biomarkers (ßa40, ßa42, ptau181, and ptau217). the diagnostic task follows an oddball paradigm, where participants must detect target images (grapes) among distractors (other fruits) across 100 one-second trials, lasting approximately three minutes. eye vergence is recorded using remote infrared eye-tracking, while participants simply fixate on a computer screen. the therapeutic aspect evaluates the impact of bgaze therapy, which employs "serious games" designed to train attentional control through eye movements. the game dynamically adjusts its difficulty in real time and provides continuous feedback to enhance user engagement and learning efficacy. participants will undergo pre-testing-including blood biomarker analysis and standardized cognitive assessments (mmse and moca)-followed by a two-month training phase at care centers using the bgaze therapy system. post-intervention testing will mirror the pre-test protocol to assess cognitive and neurological changes. a total of 60 participants (30 with mci and 30 with ad) will be recruited for the validation phase. a subsample (15 mci and 15 ad participants) will be selected for the treatment phase. ultimately, this study aims to establish bgaze as a cost-effective, scalable, and non-invasive tool for the early diagnosis and treatment of alzheimer's disease by addressing the attentional and cognitive deficits associated with the condition.


Eligibility criteria:
inclusion criteria: * aged 50 years or older. * clinical diagnosis of early-stage ad or mci based the criteria of national institute on aging-alzheimer's association. * capable of providing informed consent. exclusion criteria: * severe cognitive impairment (mmse \< 10). * neurological conditions affecting cognition (e.g., stroke). * severe psychiatric disorders. * structural brain abnormalities (e.g., tumors) with cognitive impact. * significant visual impairments. * inability to understand or communicate in spanish.
virtual reality in children with hemiparesis

Conditions: Physical Disability

Summary: children with cerebral palsy have impaired selective motor control and upper limb functions that affect their performance

twenty volunteer children diagnosed with hemiparetic cerebral palsy will be recruited from national institute of neuromotor system. they will be randomly assigned to intervention and control group.

Eligibility criteria:
inclusion criteria: * - age between 7 and 11 years * spasticity grade of 1+ or 2 on mas * level i and ii on gmfcs * level ii and iii on macs * being able to cooperate and being motivated exclusion criteria: * visual or auditory problems severe spasticity (an ashworth spasticity score of 4 in any upper or lower extremities) severe mental retardation surgeries for spasticity within the past 12 months, toxin injection within the past six months. * structural or fixed soft tissue deformities in the affected upper extremity

Keywords: cerebral palsy selective motor control upper limb coordination virtual reality
neoadjuvant nivolumab with ccr2/5-inhibitor or anti-il-8) for non-small cell lung cancer (nsclc) or hepatocellular carcinoma (hcc)

Conditions: Non-small Cell Lung Cancer; Hepatocellular Carcinoma

Summary: the purpose of this research study is to study the effect of giving nivolumab with ccr2/5-inhibitor or anti-il-8 before surgery, and after surgery, with the goal of determining if this medicine results in: 1. a significant immune response against their tumor (which the study team will see in the tumor that is taken out at the time of surgery) 2. improvement in long term survival rates

objectives: cohorts a,b (nsclc): primary objective: major pathologic response (mpr) secondary objectives: time to surgery, tolerability and safety, radiographic response cohorts c,d,e (hcc): primary objective: significant tumor necrosis (stn) secondary objectives: time to surgery, tolerability and safety, radiographic response diagnosis and main inclusion criteria: patients must have disease deemed resectable before enrollment. study product: nivolumab 480mg (q4w, dosed twice before surgery and three times following recovery from surgery) bms-813160 (ccr2/5-inhibitor) 300mg oral twice a day for 28 days bms-986253 (anti-il-8) 2400mg once

Eligibility criteria:
inclusion criteria: * diagnosis of nsclc or hcc * willing to provide blood samples * willing to undergo leukapheresis at mount sinai hospital or new york blood bank * willing to have excisional or core needle biopsies * at least 18 years of age * ecog 0-1 * surgical candidate for resection of their tumor * agree to use adequate contraception * adequate organ and marrow function exclusion criteria: * patients who have had chemotherapy or radiotherapy within 4 months for a different primary tumor or patients who have received locoregional therapy for the target lesion * patients receiving any other investigational agents * patients with metastatic disease for whom the intent of surgery would not be curative * uncontrolled intercurrent illness * pregnant or nursing * has a diagnosis of primary immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days * has active autoimmune disease that has required systemic treatment in the past year * has a known additional malignancy that is progressing and/or requires active treatment * has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not the in the best interest of the patient to participate * hiv positive with detectable viral load or anyone not on stable anti-viral regimen * has known active hepatitis b * history of allogeneic hematopoietic cell transplantation or solid organ transplantation * documented allergic or hypersensitivity response to any protein therapeutics * patients may not have prolonged qrs or qtc

Keywords: nivolumab ccr2/5-inhibitor anti-il-8
asthma-educator mobile application manage asthma

Conditions: Asthma

Summary: through this study, the investigators developed the asthma-educator mobile application, and evaluated its use among adult asthma patients at montefiore.

through this study, the investigators developed the asthma-educator mobile application, and evaluated its use through 2 phases: 1) phase 1 = process outcomes evaluation with 30 patients); and 2) phase 2 (longitudinal clinical evaluation with 40 patients receiving the intervention at baseline, 2 months, 4 months, and 6 months). the study's primary outcome is asthma control.

Eligibility criteria:
inclusion criteria: adults (\>18 years) with: (a) severe asthma (i.e. at least one asthma-related ed visit and/or hospitalization in the previous year); (b) access to a smartphone with short message service (sms) capability; (c) english speaking; (d) able to give informed consent. exclusion criteria: (a) use of oral corticosteroids in the 2 weeks prior to the baseline visit; (b) pregnancy; (c) severe psychiatric or cognitive problems that would prohibit an individual from understanding and completing the protocol; and (d) patients that previously received the asthmaxcel application.

Keywords: informatics asthma
radiographic contrast to differentiate cavitated from non-cavitated tooth decay

Conditions: Dental Caries

Summary: the proposed test is intended to enable dentists to differentiate between cavitated and non-cavitated tooth decay in the areas where teeth are in contact (interproximal surfaces). in these areas, dentists cannot visually inspect for caries, and currently bitewing x-rays (bws) only correctly detect the presence of enamel decay 15-25% of the time. this low sensitivity can lead to late treatment resulting in unnecessarily large fillings, crowns, pain, root canals, and possible later loss of teeth.

tooth sites will be recorded by both tooth number, type of surface (mesial, distal, occlusal), cavitated, non-cavitated, healthy. radiographs will similarly be scored. although contrast agents are classified as drugs this is not a study of drug properties or effect on cells since the properties of the agent are already well known and its safety record well established. this study will be recording the radiopacity of the contrast agent on healthy tooth surfaces, non-cavitated tooth surfaces and cavitated tooth surfaces. the outcome for each surface type will be presence or absence of a radiopacity on a radiograph which will be made at the one and only visit for each study subject. the radiograph contains the data from the intervention (placement of contrast agent) and the outcome will be assessed some weeks later after the completion of the data collection.

Eligibility criteria:
inclusion criteria: * must have a minimum of 2 adjacent teeth so that interproximal surfaces of interest are in contact and hidden from direct visual examination. the occlusal plane plane should be normal so that the interproximal contact regions are normal. english or spanish speaker. exclusion criteria: * pregnant women. a person who has participated in a similar study involving dental radiography within the last 12 months. fillings must not be present in the regions of interest.
developing tools for dialysis decision support

Conditions: Chronic Kidney Diseases

Summary: the aim of this study is to evaluate the impact of a web-based dialysis decision support tool on decisional conflict, and values-treatment concordance and other decisional outcomes in individuals with advanced chronic kidney disease, and to assess the tool's acceptability and usability.

this study employs a pre-post design to assess the impact of a web-based dialysis decision support tool on patients with advanced chronic kidney disease and their caregivers. participants will complete baseline surveys assessing demographics, knowledge of kidney failure treatments, and decisional conflict during a nephrology clinic visit. following the visit, participants will access the decision support tool, with follow-up support provided by the study coordinator. one to four weeks after the baseline visit, participants will complete follow-up surveys to re-evaluate knowledge, decisional conflict, values-treatment concordance, and the quality of shared decision-making. additionally, telephone interviews will be conducted to explore participants' understanding of treatment options and gather feedback on the decision support tool.

Eligibility criteria:
inclusion criteria: 1. age \&gt;=65 2. estimated gfr \&lt;25 ml/min/1.73m2 3. english speaking 4. not a candidate for kidney transplant based on nephrologist assessment. family/caregiver inclusion criteria: 1. age \&gt;=21 2. english speaking exclusion criteria: a. patients with cognitive impairment will be excluded; however their family member or caregiver is eligible to participate.
pet study with 11 c-pib to evaluate amyloid protein deposits in mild cognitive disorder, alzheimer's disease and early frontotemporal degeneration.

Conditions: Alzheimer Disease

Summary: preclinical and clinical data have demonstrated the ability of the 11c-pib tracer to selectively bind accumulations of amyloid protein, a neuropathological marker characteristic of the neurodegenerative pathologies covered by this study. the validation in larger groups of patients, and the comparison between the different clinical syndromes included in the spectrum, will allow the diagnostic and prognostic potential of the tracer to be evaluated, with important consequences for the clinical management of patients. in particular, the tracer could play a central role in the clinical management of patients with neurodegenerative diseases and cognitive impairment. numerous pharmacological trials are currently underway, worldwide, for the validation of anti-amyloid drugs. in the future we could think about early monitoring with imaging of the effectiveness of the treatment. t he fdg pet technique can be of great help in obtaining relationships between radiation damage to the brain and possibly neurological and neuropsychological deficits associates.


Eligibility criteria:
inclusion criteria: * alzheimer's diagnosis according to the diagnostic criteria in use. exclusion criteria: * current or previous treatments with neuroactive drugs; * pregnancy or breastfeeding.
guanidinoacetic acid loading for chronic fatigue syndrome

Conditions: Chronic Fatigue Syndrome

Summary: chronic fatigue syndrome (cfs) is a debilitating condition of unknown etiology. recent studies have shown that cfs is associated with impaired cellular energetics and low levels of phosphocreatine. since guanidinoacetic acid (gaa) acts as a highly bioavailable precursor of creatine it may provide an ideal dietary supplement to facilitate treatment and perhaps prevention of cfs. the overall hypothesis to be evaluated is that medium-term supplementation with gaa will improve clinical outcomes in well-defined adult cfs patients via augmented provision of creatine. specific aims: (1) to determine the effects of gaa on cfs symptomatology using a fatigue severity inventory, soreness of locomotive apparatus scales, and a health-related quality of life survey; (2) to determine the effect of gaa on creatine metabolism using laboratory studies and magnetic resonance spectroscopy; (3) to characterize the physiological effects of gaa on work capacity via actigraphy and exercise performance tests; and (4); to determine the prevalence of subjectively reported side-effects and biochemical adverse events associated with gaa intervention.

a variety of dietary interventions have been used in the management of cfs, yet no therapeutic modality demonstrated overall positive results in terms of effectiveness (whiting et al. 2001). previous studies have evaluated the effects of essential fatty acids, vitamins, minerals and/or enzymes, with findings do not support the use of a broad-spectrum nutritional supplement in treating cfs-related symptoms (brouwers et al. 2002). considering the fact that patients with cfs have lower levels of high-energy compounds (e.g. phosphocreatine, adenosine triphosphate) (block et al. 1998), effective dietary treatment of cfs should be focused on providing compounds that facilitates cellular bioenergetics. besides other candidate agents, guanidinoacetic acid (gaa) could be of particular interest since it occurs naturally in the human body and acts as an immediate precursor of creatine (wyss and kaddurah-daouk, 2000). due to its low cost and high bioavailability (baker 2009), if proven effective dietary gaa may be suitable for use in broad cfs population.

Eligibility criteria:
inclusion criteria: * adults who fulfilled the 1994 cdc criteria for cfs * older than 18 years of age will be candidates for inclusion in the study. exclusion criteria: * psychiatric comorbidity * use of any dietary supplement within 4-weeks prior to the study commencing * pregnant

Keywords: creatine guanidinoacetic acid intervention fatigue muscle strength
hct effect among patients with psychotic disorders

Conditions: Psychotic Disorders

Summary: horticulture therapy has been found to have positive effects on individuals with psychotic disorders, promoting social interaction, reducing social isolation, and improving cognitive function. effectiveness of horticulture therapy in enhancing well-being, reducing symptoms, and facilitating social adjustment in this population

horticulture therapy involves gardening and plant-related activities as a form of therapeutic intervention, enhance patient to be mindful to current environment and promote relaxation which can reduce symptoms such as anxiety, depression, and social isolation, improve cognitive function, and promote overall well-being .with this respect, there is an urgent need to find a sustainable and eco-friendly solution for this complex issue by returned to nature and utilizing the low cost and current resources at the same time to make a signification reduction in the psychotic disorder's symptoms

Eligibility criteria:
inclusion and exclusioncriteria: did not undergo any other intervention during the ht program used in the study, just routine care in hospital -

Keywords: hope psychological adjustment psychological wellbeing horticulture therapy
effect of restriction of foods containing phosphorus additives

Conditions: End-stage Renal Disease; Hyperphosphatemia

Summary: hyperphosphatemia is related to the increase in morbidity and mortality. there is greater risk for cardiovascular disease, atherosclerotic disease, secondary hyperparathyroidism, and bone disease . the serum phosphorus level can be controlled by a combination of factors, such as: reduction of ingestion, reduction of intestinal absorption with chelating agents and increase in elimination by dialysis. the purpose of this study is to evaluate the effect of dietary intervention consisting of the restriction of industrialized foods with phosphorus additives in chronic kidney disease patients treated with hemodialysis.

the consumption of foods which contain phosphorus by patients on hemodialysis should be monitored in order to reflect the current reality, due to the increase in ingestion of industrialized foods rich in phosphorus additives. data from studies performed in the usa shows a reduction in phosphatemia with nutritional orientation to reduce foods containing additives from restaurants in the region of the study . in another study, also conducted in the usa, the researchers evaluated the phosphorus content and presence of additives in appetizers and side orders served at fast food restaurants in cleveland. the results showed that of the appetizers, 52% were accepted by the traditional criteria for the renal diet (low content of sodium, potassium and organic or natural phosphorus), but only 16% were also free of phosphorus additives; of the side orders, 23% were accepted by the traditional criteria and 17% were exempt of phosphorus additives. thus, only a small proportion of appetizers and side orders served at fast food restaurants were compatible with the renal diet. considering that alimentary phosphorus has an important role in the control of phosphatemia, there is a lack of studies which evaluates the effect of foods containing phosphorus additives on phosphatemia and which, at the same time, evaluated the alimentary ingestion and the nutritional state of the chronic kidney disease patients treated with hemodialysis. can the elimination of foods containing phosphorus additives and their substitution for foods without additives reduce phosphatemia without altering the nutritional state of hyperphosphatemic patients on hemodialysis?

Eligibility criteria:
inclusion criteria: * males or female ≥ 18 years of age * chronic kidney disease in stage 5, on hemodialysis for at least 6 months * serum phosphorus (p) greater than 5.5 mg/dl persistent in 3 previous months * preserved cognitive capacity and able to read and write * signed informed written consent exclusion criteria: * use of enteral or parenteral therapy * presence of physical or cognitive limitation * malabsorption diseases.

Keywords: dialysis phosphorus diet